SpineThera Announces Results for SX600 from its SALIENT Phase 2 Sciatica Pain Clinical Trial Support

PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection [TF-EI] for the management of sciatica pain) today announced promis...

Related Keywords

Adelaide ,South Australia ,Australia ,Minnesota ,United States ,University Of Adelaide ,Turkey ,Turk ,Jeff Missling ,Clinical Research ,Initiative On Methods ,Spinethera Inc ,Oswestry Disability Index ,Spain Assessment ,Clinical Trials ,Guy Ludbrook ,Royal Adelaide Hospital ,Acute Care Medicine ,Principal Investigator ,Bill Houghton ,Chief Medical Officer ,Medical Director ,Medical Alley ,